Abstract
Placenta-mediated pregnancy complications, including pre-eclampsia, placental abruption, birth of a small-for-gestational age infant and late pregnancy loss, are common and cause significant morbidity and mortality. The use of antepartum low-molecular-weight heparin (LMWH) prophylaxis to prevent recurrent placenta-mediated pregnancy complications became common practice despite limited and conflicting evidence supporting its use. Unfortunately, differences in the study design of individual randomized controlled trials have limited comparison across trials. In this talk we will review data from an individual patient data meta-analysis that challenges the role of LMWH in preventing recurrent placenta-mediated pregnancy complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
